Table 3. Concomitant medications usage of participants.
| Concomitant medication | Decaffeinated EGCG (n = 39) | Placebo(cellulose) (n = 38) | P value |
| Antidiabetic medications users, % | 53.8 | 60.5 | 0.097 |
| Sulfonylureas, % | 35.9 | 34.2 | 0.877 |
| Biguanides, % | 43.6 | 44.7 | 0.919 |
| Alpha glucosidase inhibitors, % | 2.6 | 5.3 | 0.541 |
| Thiazolidinediones, % | 12.8 | 5.3 | 0.249 |
| Dipeptidyl peptidase 4 (DPP-4) inhibitors, % | 10.3 | 5.3 | 0.414 |
| Meglitinide, % | 2.6 | 0 | 0.320 |
| Combination, % | 35.9 | 26.3 | |
| Antihypertensives users, % | 15.4 | 10.5 | 0.787 |
| Angiotensin-converting enzyme inhibitors, % | 2.6 | 2.6 | 0.985 |
| Angiotensin receptor blockers, % | 10.3 | 7.9 | 0.719 |
| Calcium channel blockers, % | 7.7 | 2.6 | 0.317 |
| Combination, % | 5.1 | 2.6 | |
| Lipid modifying agents users, % | 15.4 | 5.3 | 0.146 |
| HMG CoA reductase inhibitors,% | 12.8 | 5.3 | 0.249 |
| Fibrates, % | 2.6 | 0 | 0.320 |
| Combination, % | 0 | 0 |
Data analyzed by Chi-square test, except the mean of different medication analyzed by independent t-test.